Joincare(SH:600380) Cai Jing Wang·2026-01-08 07:39Core Viewpoint - Health元's subsidiary, Zhuhai Lizhu Biotech Co., Ltd., has announced that its product, Lakanqita monoclonal injection, has been included in the priority review and approval process as of December 26, 2025, marking its entry into the priority review stage for drug marketing authorization [1] Group 1 - The drug is intended for adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy [1] - Lakanqita monoclonal injection is the first domestically developed and the second globally in progress IL-17A/F dual-target inhibitor [1] - The clinical trial, which was multi-center, randomized, double-blind, and positive-controlled, was completed in July 2025, showing that the drug is more effective than the comparator, Secukinumab, with good safety [1] Group 2 - Although the drug application has been accepted, it still requires evaluation and on-site inspection, leaving uncertainty regarding the final approval and market launch timing [1]